Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Accumulated Expenses (2016 - 2025)

Celldex Therapeutics has reported Other Accumulated Expenses over the past 16 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $1.2 million for Q4 2025, up 30.57% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 30.57% YoY), and the annual figure for FY2025 was $1.2 million, up 30.57%.
  • Other Accumulated Expenses for Q4 2025 was $1.2 million at Celldex Therapeutics, up from $930000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CLDX hit a ceiling of $7.6 million in Q1 2021 and a floor of $283000.0 in Q4 2021.
  • Median Other Accumulated Expenses over the past 5 years was $1.3 million (2022), compared with a mean of $2.1 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 296.42% in 2024 and later crashed 74.68% in 2025.
  • Celldex Therapeutics' Other Accumulated Expenses stood at $283000.0 in 2021, then soared by 249.82% to $990000.0 in 2022, then crashed by 61.82% to $378000.0 in 2023, then surged by 149.21% to $942000.0 in 2024, then surged by 30.57% to $1.2 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $1.2 million (Q4 2025), $930000.0 (Q3 2025), and $930000.0 (Q2 2025) per Business Quant data.